{
    "nctId": "NCT01038804",
    "briefTitle": "A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer",
    "officialTitle": "A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 101,
    "primaryOutcomeMeasure": "Progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically- or cytologically-proven adenocarcinoma of the breast that is HER2 negative. Subjects with hormone receptor positive or negative status are eligible. Additionally, subjects with triple negative status (meaning estrogen receptor negative, progesterone receptor negative and HER2 negative) are eligible\n* No prior chemotherapy regimen for metastatic breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1 at the Baseline Visit\n* The subject's life expectancy is estimated to be \\> 12 weeks at the Baseline Visit\n* The subject must be non-pregnant and non-lactating. All sexually active subjects of childbearing potential must agree to use an adequate method of contraception throughout the study period\n\nExclusion Criteria:\n\n* Hypersensitivity to docetaxel or polysorbate 80\n* Neuropathy \u2265 Grade 2 at the Baseline Visit\n* Known brain or leptomeningeal metastasis as assessed through medical history review and physical examination\n* The subject has known Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen or hepatitis C antibody",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}